Article
Oncology
Haixiu Liao, Meng Ding, Nannan Zhou, Ying Yang, Liwen Chen
Summary: This study reveals that B7-H3 induces the upregulation of SIRT1 expression via the PI3K/AKT pathway, thereby promoting the metastasis of NSCLC. B7-H3 depletion and SIRT1 silencing inhibit the EMT process and reduce the migration and invasion abilities of NSCLC cells.
MOLECULAR MEDICINE REPORTS
(2022)
Article
Oncology
Meiyun Sun, Jinjing Xie, Dongze Zhang, Chunyang Chen, Simin Lin, Yan Chen, Guangbo Zhang
Summary: In this study, it was found that B7-H3 inhibits the apoptosis of gastric cancer cells through the regulation of the FN-mediated PI3K/AKT signaling pathway.
Article
Oncology
Ji Liu, Aimaitiaji Kadier, Yadong Guo, Wentao Zhang, Haotian Chen, Zhijin Zhang, Changcheng Guo, Yue Zhang, Meiyu Bao, Jiang Geng, Junfeng Zhang, Shiyu Mao, Xudong Yao
Summary: Through transcriptomic and proteomic analyses, CD276 was identified as a potential target for immunotherapy. In vivo and in vitro experiments confirmed its role in mediating immunotherapeutic effects. CD276 was found to inhibit the enrichment of CD8+ T cells in prostate cancer, suggesting that CD276 inhibitors may be potential targets for immunotherapy.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Article
Immunology
Zheng-Yan Li, Jin-Tao Wang, Gang Chen, Zhi-Guo Shan, Ting-Ting Wang, Yang Shen, Jun Chen, Zong-Bao Yan, Liu-Sheng Peng, Fang-Yuan Mao, Yong-Sheng Teng, Jin-Shan Liu, Yuan-Yuan Zhou, Yong-Liang Zhao, Yuan Zhuang
Summary: In gastric cancer tumors, neutrophils expressing CD54 and B7-H3 are closely associated with changes in GM-CSF levels, activating through the JAK-STAT3 signaling pathway. B7-H3+ neutrophils may potentially serve as biomarkers in gastric cancer, increasing with tumor progression and predicting overall survival.
CLINICAL IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Heng-Jia Liu, Heng Du, Damir Khabibullin, Mahsa Zarei, Kevin Wei, Gordon J. Freeman, David J. Kwiatkowski, Elizabeth P. Henske
Summary: This study reveals that B7-H3 expression is correlated with immunosuppressive phenotypes and worse clinical outcomes in human tumors with high mTORC1 activity. The authors show that mTORC1 upregulates B7-H3 expression by phosphorylating the transcription factor YY2. Inhibiting B7-H3 enhances T-cell activity and induces tumor cell expression of MHC-II, suppressing tumor growth with mTORC1 hyperactivity.
NATURE COMMUNICATIONS
(2023)
Article
Immunology
Martina S. S. Lutz, Latifa Zekri, Laura Wessling, Susanne Berchtold, Jonas S. S. Heitmann, Ulrich M. M. Lauer, Gundram Jung, Helmut R. R. Salih
Summary: T cell-based immunotherapy has significantly improved treatment options for many malignancies. However, gastrointestinal cancers such as pancreatic, hepatic and gastric cancer still have high relapse rates and poor prognosis. A novel bispecific antibody called CC-3 with B7-H3xCD3 specificity has been preclinically characterized and shown to induce strong T cell reactivity against these cancer types, leading to target cell lysis and T cell memory formation. This antibody has the potential to be clinically evaluated for the treatment of pancreatic, hepatic and gastric cancer.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Siji Chen, Shenghua Zhan, Sisi Ding, Qiange Zhang, Hanqin Xuan, Xueguang Zhang, Lei Cao
Summary: The co-expression of B7-H3 and CD47 in gastric cancer patients is associated with poor prognosis, and their expression in tumor tissue is accompanied by macrophage infiltration.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Medicine, Research & Experimental
Supreet Agarwal, Lei Fang, Kerry Mcgowen, Juanjuan Yin, Joel Bowman, Anson T. Ku, Aian Neil Alilin, Eva Corey, Martine P. Roudier, Lawrence D. True, Ruth Dumpit, Ilsa Coleman, John K. Lee, Peter S. Nelson, Brian J. Capaldo, Aida Mariani, Clare Hoover, Ilya S. Senatorov, Michael Beshiri, Adam G. Sowalsky, Elaine M. Hurt, Kathleen Kelly
Summary: This study provides a comprehensive analysis of a B7H3-ADC therapy in metastatic prostate cancer models. It reveals that B7H3 expression alone is not sufficient for responsiveness, and identifies RB1 deficiency and replication stress as predictors of sensitivity. The findings suggest that biomarker-driven trial designs can maximize clinical benefit of ADC therapies.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Oncology
Chunxia Zhang, Yinshuang Chen, Fuchao Li, Man Yang, Fanyi Meng, Yawen Zhang, Weichang Chen, Weipeng Wang
Summary: The study identified SRSF3 as a splicing factor involved in the regulation of B7-H3 expression, impacting the prognosis of CRC patients. High expression of SRSF3 and B7-H3 correlates with poor patient outcomes, suggesting SRSF3 as a potential target for regulating B7-H3 expression and CRC therapy.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Medicine, Research & Experimental
Keywan Mortezaee
Summary: B7-H3 is a checkpoint that is overexpressed in several human cancers and associated with poor prognosis. It drives immune evasion by impairing T cell infiltration and promoting CD8+ T cell exhaustion. High B7-H3 activity also induces pro-tumor macrophage polarization and aberrant angiogenesis, leading to resistance to immune checkpoint inhibitor therapy. Targeting B7-H3 in cancer immunotherapy holds promise as a desired approach.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Article
Chemistry, Medicinal
Beiwei Liang, Chunlai Li, Zhan Zhou, Yubo Xie
Summary: This study aimed to investigate the effect of hydromorphone on the growth of human gastric cancer cells. The results showed that within a certain concentration range, hydromorphone can suppress the growth of human gastric cancer cells, and the inhibitory effect is enhanced with longer incubation time and higher concentrations. Hydromorphone inhibits the growth of human gastric cancer cells through cell cycle arrest and induction of apoptosis.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2023)
Article
Oncology
Lili Huang, Yan Zhou, Qiuwei Sun, Lei Cao, Xueguang Zhang
Summary: The levels of soluble B7-H3 in both serum and tissue of gastric adenocarcinoma (GAC) patients were significantly higher compared to gastritis patients and healthy controls. The level of soluble B7-H3 was correlated with the expression of B7-H3 in tissues, and it was associated with clinical pathological characteristics of GAC patients.
Article
Biochemistry & Molecular Biology
Eugene Shenderov, Angelo M. M. De Marzo, Tamara L. L. Lotan, Hao Wang, Sin Chan, Su Jin Lim, Hongkai Ji, Mohamad E. E. Allaf, Carolyn Chapman, Paul A. A. Moore, Francine Chen, Kristina Sorg, Andrew M. M. White, Sarah E. E. Church, Briana Hudson, Paul A. A. Fields, Shaohui Hu, Samuel R. R. Denmeade, Kenneth J. J. Pienta, Christian P. P. Pavlovich, Ashley E. E. Ross, Charles G. G. Drake, Drew M. M. Pardoll, Emmanuel S. S. Antonarakis
Summary: B7-H3-targeting antibody enoblituzumab has shown potential clinical activity and safety in treating high-risk localized prostate cancer.
Article
Immunology
Chao Lv, Shukun Han, Baokang Wu, Zhiyun Liang, Yang Li, Yizhou Zhang, Qi Lang, Chongli Zhong, Lei Fu, Yang Yu, Feng Xu, Yu Tian
Summary: This study developed immune scoring systems focusing on B7-H3, B7-H4, and HHLA2, and demonstrated their potential in predicting survival and immunotherapeutic efficacy for gallbladder cancer (GBC). The results showed that these immune scoring systems were associated with worse clinicopathological stage and unfavorable prognosis in postoperative survival. Additionally, novel prediction models based on immune stratification and TNM staging showed excellent discrimination ability in predicting survival and immunotherapeutic efficacy for GBC patients.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Wei Zhang, Lingyi Zhang, Jun Qian, Jiang Lin, Qiaoyun Chen, Qian Yuan, Jingdong Zhou, Tingjuan Zhang, Jinning Shi, Hong Zhou
Summary: The study found that 2Ig mRNA and total B7-H3 membrane protein in AML may have potential diagnostic value, with high expression indicating worse overall survival. The expression of 4Ig and 2Ig was found to be methylation-independent in AML.
